During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myleoma Hub was pleased to speak to Adam Cohen, University of Pennsylvania, Philadelphia, US. In this podcast, he discussed the use of BFCR4350A, a novel bispecific FcRH5:CD3 T-cell engaging antibody, in patients with relapsed/refractory multiple myeloma.

Adam Cohen provides us with insights from pre-clinical data and explains the mechanism of action of BFCR4350A. He also describes the expression patterns of its target FcRH5, which make this drug less likely to have off-target effects and be specifically efficacious in patients with an amplification at the 1q21 locus. He also discusses the study design, criteria, and objectives of the phase I trial, including a step-up dosing regimen aimed to mitigate cytokine syndrome and neurotoxicity.

Hosted on Acast. See acast.com/privacy for more information.